Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
نویسندگان
چکیده
منابع مشابه
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
AIM To compare treatment costs with alternative luteinizing hormone-releasing hormone (LHRH) agonist preparations and determine whether a leuprorelin solid implant is associated with potential cost savings. PATIENTS & METHODS A hypothetical population of 1000 prostate cancer patients was apportioned between the three most commonly-prescribed LHRH agonist preparations. Differentiated annual co...
متن کاملLuteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
This article reviews the evidence underlying hormone treatment decisions for men with advanced prostate cancer. Luteinizing hormone-releasing hormone (LHRH) analogs are the mainstays of therapy, but 3 areas of LHRH use need clarification: (1) when to start therapy, (2) what alternatives are available, and (3) how to incorporate a long-term strategy for the individual patient. The Medical Resear...
متن کاملSomatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
The combination of a long-acting delivery system for the agonist [D-Trp6]luteinizing hormone-releasing hormone ([D-Trp6]LH-RH) with modern somatostatin analogs was studied in the Dunning R-3327H rat prostate cancer model. Microcapsules of [D-Trp6]LH-RH releasing 25 micrograms/day were injected once a month. In the first experiment the adjunct was the somatostatin analog D-Phe-Cys-Tyr-D-Trp-Lys-...
متن کاملLuteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
Substitution at positions 6 and 10 can result in super-active peptides. Therefore, several LHRH analogues substituted at position 6, 10, or both are much more active than LHRH and have prolonged activity [5]. Of these analogues, the most important are [D-Trp 6 ]LHRH (triptorelin), [D-Leu 6 ,Pro 9 NHET]LHRH (leuprolide), [D-Ser(Bu t ) 6 ,Pro 9 NHET]LHRH (buserelin), and [D-Ser(Bu t ) 6 ,AzaGly 1...
متن کاملAcute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.
BACKGROUND Meningiomas are the most common type of benign brain tumor, and the incidence of meningioma in women is more than twofold higher than in men. Several studies have demonstrated that hormones are somehow related to the growth of meningiomas. CASE DESCRIPTION A 72-year-old man with benign meningioma underwent tumor resection and had no recurrence for 18 years. He was found to have pro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Pharmacotherapy
سال: 2017
ISSN: 1465-6566,1744-7666
DOI: 10.1080/14656566.2017.1328056